Snapshot: Companion Diagnostics Market Grows Rapidly

June 3, 2016
Snapshot: Companion Diagnostics Market Grows Rapidly
Last October, the FDA approved the first drug-diagnostic combination for lung cancer. [NIH]

Alex Philippidis

Two reports on the global companion diagnostics market published in recent weeks offer differing numbers, and explanations, but come to the same conclusion: The market will continue growing rapidly over the next few years.

Transparency Market Research projects the global CDx market will have more than tripled between 2013 and 2019, multiplying from $1.8 billion in 2013 to $5.6 billion in 2019. The firm is basing its forecast on companion diagnostics sustaining a compound annual growth rate of 18%.

While the largest share of companion diagnostics has focused on detecting breast cancer, the discovery of lung cancer specific biomarkers will enable lung cancer-focused companion diagnostics to grow at a CAGR of more than 20% through 2019, the firm added.

To read the full contents of this article click here.

×

Oops! Please type your email in the following format: yourname@example.com.

You’re all set!
Thank you for subscribing to
Clinical OMICs Weekly
.